refine: phase ii study of navitoclax ruxolitinib in jak inhibitor-naive patients with mf
Published 2 years ago • 251 plays • Length 2:12Download video MP4
Download video MP3
Similar videos
-
1:39
refine: updated data on navitoclax and ruxolitinib for myelofibrosis
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
1:45
a phase ii study of elritercept for lower-risk mds
-
1:20
the impact of early ruxolitinib treatment on os in the comfort-i and comfort-ii studies
-
1:22
managing cytopenias following jak inhibitor treatment & achieving true disease modification in mf
-
3:13
therapies for patients who progress on jak inhibitors: imetelstat, navtemadlin, selinexor & tp-3654
-
5:00
long-term results of the phase ii revive study evaluating rusfertide in patients with pv
-
2:42
the impact of jak2 allele burden and cytopenia on mf outcome in the era of ruxolitinib
-
11:02
how to obtain viable cardiomyocytes from resected mouse hearts
-
20:26
3mensio ct pre-case planning: redo-tavr with prior sapien 3 (2 of 2)
-
4:59
behind the mystery, polycythemia vera
-
1:07
advancements in combination strategies with jak inhibitors for myelofibrosis
-
4:48
an insight into the management of cytopenias in mf
-
1:18
results of a phase i study of sonrotoclax for the treatment of r/r waldenström’s macroglobulinemia
-
2:05
a phase ii study investigating epcoritamab in the treatment of waldenström’s macroglobulinemia
-
3:51
future jak inhibitor combination approaches in myelofibrosis
-
2:04
introducing a phase ib/ii trial to evaluate tasquinimod for the treatment of myelofibrosis
-
2:06
second-line myelofibrosis treatment – the potential of jak2 inhibitor ns-018
-
1:40
results from a phase i/ii study of golcadomide in r/r follicular lymphoma
-
1:46
ruxolitinib in 2024 and beyond: the good, the suboptimal, and the failure
-
1:52
evaluating the efficacy of obinutuzumab, ibrutinib, and venetoclax in richter's transformation
-
2:03
an update on the phase ii/iii imerge trial of imetelstat in lr-mds